Opportunity Information: Apply for RFA DA 10 016
Apply for RFA DA 10 016
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Medications Development for Cannabis Related Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 24, 2009 and posted on Sep 24, 2009.
- Applicants must submit their applications by Apr 30, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: For profit organizations other than small businesses City or township governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Small businesses Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Medications Development for Cannabis Related Disorders (R01) opportunity (Funding Opportunity Number RFA-DA-10-016) was a National Institutes of Health (NIH) request for applications aimed at speeding up the development of medications for problems linked to cannabis use. The central goal was to support research that identifies promising medication candidates and then tests them in either preclinical models or in human studies, with an emphasis on finding treatments that are both safe and effective. The scope covered cannabis use disorder and other cannabis-induced disorders, and it also explicitly included the medical and psychiatric consequences that can accompany cannabis use, meaning applicants could focus on downstream health impacts as long as the work was tied to medication development and evaluation.
This funding announcement used the R01 grant mechanism, which generally supports mature, hypothesis-driven projects and larger research programs compared to exploratory mechanisms. The FOA also noted that it ran in parallel with two other NIH announcements of the same scientific scope (PA-07-365 and PA-07-366) that invited applications under the R01 and R21 mechanisms, respectively. In practical terms, this indicated a broader NIH effort in this topic area, giving investigators multiple routes depending on the maturity and scale of their proposed studies, while this specific announcement targeted the R01 format under an RFA structure.
On the research side, the announcement was flexible about the stage of development: projects could be preclinical or could be clinical trials that fit the FDA-defined Phase I, Phase II, or Phase III categories. That range suggests NIH was interested in supporting the full pipeline from early testing through later-stage efficacy work, as long as the proposal was clearly focused on medication development for cannabis-related conditions. It also implies that applicants needed to be explicit about trial phase, safety monitoring, and the clinical endpoints appropriate to the stage of testing, since the FOA framed clinical work in standard FDA trial terms.
In terms of funding, NIH anticipated making about six awards with an estimated total funding level of $3,000,000. The listed award ceiling was $500,000, which signals the approximate maximum size NIH expected per award under this competition (though actual budgets would typically depend on project needs and NIH approval). There was no cost sharing or matching requirement, which reduces administrative burden for applicants and indicates NIH intended to cover allowable project costs without requiring non-federal matching funds.
Eligibility was broad and included many common research-performing organizations and public entities. Eligible applicants included for-profit organizations (including small businesses), nonprofits with and without 501(c)(3) status, public and private institutions of higher education, and a range of government entities (state, county, city/township, special district, and independent school districts). It also included Native American tribal governments (both federally recognized and other than federally recognized) and tribal organizations, as well as public housing authorities/Indian housing authorities. The FOA additionally called out a variety of specific eligible categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based and community-based organizations, eligible federal agencies, U.S. territories or possessions, and non-U.S. entities (foreign organizations) and regional organizations. This breadth suggests NIH wanted to encourage applications from diverse institutional types, including those serving historically underrepresented communities and, where relevant, international partners.
Administratively, the opportunity was posted on September 24, 2009, with an original (and final) closing date of April 30, 2010, and it was archived on May 31, 2010. The program fell under CFDA number 93.279 (Drug Abuse and Addiction Research Programs), aligning it with NIH and addiction research funding streams. The awarding agency was NIH, and the announcement provided a link to the full FOA and contact information through the NIH Office of Extramural Research (OER) web support for access or technical linking issues.
Frequently Asked Questions (FAQs)
What is the Medications Development for Cannabis Related Disorders (R01) opportunity?
This opportunity was a National Institutes of Health (NIH) Request for Applications (RFA) focused on speeding up the development of medications for problems linked to cannabis use. It supported projects that identify promising medication candidates and test them in preclinical models or in human studies, with an emphasis on treatments that are safe and effective.
What is the Funding Opportunity Number for this grant?
The Funding Opportunity Number (FON) is RFA-DA-10-016.
Which agency offered this funding opportunity?
The awarding agency was the National Institutes of Health (NIH).
What is the main goal of the research supported by this FOA?
The central goal was to support research that moves medication candidates forward by identifying promising treatments and evaluating them through preclinical testing and/or human studies, with a clear focus on safety and effectiveness for cannabis-related conditions.
What topics and conditions were within the scope of this FOA?
The scope included cannabis use disorder and other cannabis-induced disorders. It also explicitly included medical and psychiatric consequences that can accompany cannabis use, as long as the proposed work was tied to medication development and evaluation.
Does the FOA allow projects focused on downstream health impacts of cannabis use?
Yes. Applicants could focus on downstream medical and psychiatric consequences associated with cannabis use, provided the project was clearly connected to developing and evaluating medications for cannabis-related disorders.
What grant mechanism did this opportunity use?
This announcement used the NIH R01 grant mechanism, which generally supports mature, hypothesis-driven research projects and larger research programs compared to exploratory mechanisms.
Were there related NIH opportunities with the same scientific scope?
Yes. The FOA noted it ran in parallel with two other NIH announcements of the same scientific scope: PA-07-365 (R01 mechanism) and PA-07-366 (R21 mechanism). This provided multiple routes depending on the maturity and scale of the proposed study.
What stages of medication development were eligible under this FOA?
The announcement was flexible and allowed both preclinical projects and clinical trials. Clinical studies could align with FDA-defined Phase I, Phase II, or Phase III categories.
Does the FOA support clinical trials, and if so, which phases?
Yes. The FOA allowed clinical trials fitting FDA-defined Phase I, Phase II, or Phase III categories.
What does it imply that clinical studies were framed in FDA Phase I-III terms?
It implies that applicants needed to clearly identify the trial phase and align study design elements (such as safety monitoring and appropriate clinical endpoints) with what is expected at that stage of testing, since the FOA described clinical work using standard FDA trial terminology.
How many awards did NIH anticipate making?
NIH anticipated making about six awards under this competition.
What was the estimated total funding level for this FOA?
The estimated total funding level was $3,000,000.
Was there an award ceiling, and what was it?
Yes. The listed award ceiling was $500,000, indicating the approximate maximum size NIH expected per award for this competition (with actual budgets typically depending on project needs and NIH approval).
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
What types of organizations were eligible to apply?
Eligibility was broad and included for-profit organizations (including small businesses), nonprofits with and without 501(c)(3) status, public and private institutions of higher education, and multiple types of government entities (state, county, city/township, special district, and independent school districts).
Were tribal entities and tribal organizations eligible?
Yes. Eligible applicants included Native American tribal governments (federally recognized and other than federally recognized) as well as tribal organizations.
Were public housing authorities eligible?
Yes. Public housing authorities/Indian housing authorities were listed as eligible applicants.
Did the FOA encourage applications from institutions serving historically underrepresented communities?
The FOA explicitly called out eligibility for multiple categories such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions, among others.
Were faith-based and community-based organizations eligible to apply?
Yes. Faith-based and community-based organizations were included among the eligible categories.
Could federal agencies apply under this FOA?
Yes. Eligible federal agencies were listed as eligible applicants.
Were U.S. territories or possessions included in eligibility?
Yes. U.S. territories or possessions were explicitly included in the eligibility list.
Were non-U.S. (foreign) organizations eligible?
Yes. The eligibility list included non-U.S. entities (foreign organizations) and regional organizations.
When was this funding opportunity posted?
The opportunity was posted on September 24, 2009.
What was the application closing date?
The original (and final) closing date was April 30, 2010.
Is this FOA still active?
No. It was archived on May 31, 2010.
What CFDA number was associated with this program?
The program fell under CFDA number 93.279 (Drug Abuse and Addiction Research Programs).
Where could applicants find the full FOA and get help with access or linking issues?
The announcement indicated that the full FOA and contact information were available through the NIH Office of Extramural Research (OER) web support, particularly for access or technical linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Continuum of Care Homeless Assistance Program
Previous opportunity: Disaster Resilience for Rural Communities
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) Apply for PAR 10 003 Funding Number: PAR 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 10 002 Funding Number: PAR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 10 001 Funding Number: PAR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 10 011 Funding Number: PA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 10 013 Funding Number: PA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 10 002 Funding Number: RFA CA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) Apply for RFA CA 10 003 Funding Number: RFA CA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 10 005 Funding Number: RFA CA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) Apply for RFA CA 10 004 Funding Number: RFA CA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) Apply for PAR 10 020 Funding Number: PAR 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| AIDS Science Track Award for Research Transition (R03) Apply for PAR 10 021 Funding Number: PAR 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| State and Community Tobacco Control Policy and Media Research (U01) Apply for RFA CA 10 008 Funding Number: RFA CA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effectiveness Research on Smoking Cessation in Hospitalized Patients (U01) Apply for RFA HL 10 020 Funding Number: RFA HL 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 10 025 Funding Number: PA 10 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.